BIOMARIN PHARMACEUTICAL INC
NASDAQ: BMRN (BioMarin Pharmaceutical Inc.)
Last update: 3 hours ago53.70
-0.04 (-0.07%)
| Previous Close | 53.74 |
| Open | 53.75 |
| Volume | 1,606,694 |
| Avg. Volume (3M) | 2,678,014 |
| Market Cap | 10,316,539,904 |
| Price / Earnings (TTM) | 19.96 |
| Price / Earnings (Forward) | 10.81 |
| Price / Sales | 3.42 |
| Price / Book | 1.70 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2026 |
| Profit Margin | 17.76% |
| Operating Margin (TTM) | 30.05% |
| Diluted EPS (TTM) | 2.70 |
| Quarterly Revenue Growth (YOY) | 14.80% |
| Quarterly Earnings Growth (YOY) | 109.40% |
| Total Debt/Equity (MRQ) | 10.39% |
| Current Ratio (MRQ) | 5.52 |
| Operating Cash Flow (TTM) | 700.26 M |
| Levered Free Cash Flow (TTM) | 411.56 M |
| Return on Assets (TTM) | 6.38% |
| Return on Equity (TTM) | 9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BioMarin Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.20 |
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 98.91% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dodge & Cox | 30 Sep 2025 | 14,686,801 |
| Viking Global Investors Lp | 30 Sep 2025 | 8,322,179 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 119.00 (JP Morgan, 121.60%) | Buy |
| Median | 80.00 (48.98%) | |
| Low | 55.00 (HC Wainwright & Co., 2.42%) | Hold |
| Average | 79.00 (47.11%) | |
| Total | 6 Buy, 3 Hold | |
| Avg. Price @ Call | 53.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 03 Dec 2025 | 60.00 (11.73%) | Hold | 54.31 |
| Stifel | 06 Nov 2025 | 61.00 (13.59%) | Hold | 51.84 |
| 28 Oct 2025 | 73.00 (35.94%) | Buy | 53.49 | |
| Bernstein | 03 Nov 2025 | 88.00 (63.87%) | Buy | 52.85 |
| Barclays | 28 Oct 2025 | 80.00 (48.98%) | Buy | 53.49 |
| Morgan Stanley | 28 Oct 2025 | 98.00 (82.50%) | Buy | 53.49 |
| Truist Securities | 28 Oct 2025 | 80.00 (48.98%) | Buy | 53.49 |
| Wells Fargo | 28 Oct 2025 | 70.00 (30.35%) | Buy | 53.49 |
| HC Wainwright & Co. | 27 Oct 2025 | 55.00 (2.42%) | Hold | 52.67 |
| JP Morgan | 09 Oct 2025 | 119.00 (121.60%) | Buy | 53.85 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HARDY ALEXANDER | - | 55.03 | -16,570 | -911,847 |
| Aggregate Net Quantity | -16,570 | |||
| Aggregate Net Value ($) | -911,847 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 55.03 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HARDY ALEXANDER | Officer | 01 Dec 2025 | Disposed (-) | 16,570 | 55.03 | 911,847 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |